Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension

Andreas Schneider, Bernhard M. W. Schmidt(Friedrich-Alexander-Universität Erlangen-Nürnberg), Roland E. Schmieder, Tatjana Kalizki(Friedrich-Alexander-Universität Erlangen-Nürnberg), Annemarie Reinold(Friedrich-Alexander-Universität Erlangen-Nürnberg), Johannes Schwab(Goethe University Frankfurt), Marina V. Karg(Friedrich-Alexander-Universität Erlangen-Nürnberg), Markus P. Schneider
Journal of Hypertension
January 24, 2017
10.1097/hjh.0000000000001264
Cited by 23

Related Papers

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
|The Lancet|2010|2.2k
Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
|The Lancet|2018|775
Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial
|The Lancet|2017|734
Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial
|The Lancet|2020|586
Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Events
|JAMA|2011|566